Related Experiment Video

Updated: May 28, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Pharmacotherapy of mild cognitive impairment

Serge Gauthier1

  • 1Director, Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Montreal, Canada.

Dialogues in Clinical Neuroscience
|October 29, 2011
PubMed

Insights

Acetylcholinesterase inhibitors show limited short-term cognitive benefits for amnestic mild cognitive impairment (MCI). Long-term use may slow dementia conversion, particularly in APOE-4 carriers.

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Background:

  • Amnestic mild cognitive impairment (MCI) is a high-risk state for Alzheimer's disease (AD) development.
  • MCI is considered a prodromal stage of AD, necessitating early intervention strategies.

Purpose of the Study:

  • To evaluate the efficacy of acetylcholinesterase inhibitors in treating amnestic MCI.
  • To assess the symptomatic benefit and disease-modifying potential of these drugs in the MCI prodromal stage.

Main Methods:

  • Review of randomized clinical trials comparing acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) with placebo.
  • Analysis of short-term (6-month) and long-term (3-year) study outcomes on cognition and dementia conversion.

Main Results:

  • Donepezil demonstrated symptomatic cognitive benefit in a short-term study.
  • Long-term donepezil use showed a trend towards reduced dementia conversion, sustained only in APOE-4 mutation carriers.
  • Galantamine and rivastigmine study results are pending or ongoing.

Conclusions:

  • Systematic use of acetylcholinesterase inhibitors in amnestic MCI is currently not recommended.
  • Studies in MCI provide valuable insights for testing disease-modification hypotheses in Alzheimer's disease.
Keywords:
acetylcholinesterase inhibitoramnestic subtypeclinical trialmild cognitive impairment

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications